Emerging molecular therapies of advanced thyroid cancer
- 30 April 2010
- journal article
- review article
- Published by Elsevier BV in Molecular Aspects of Medicine
- Vol. 31 (2), 215-226
- https://doi.org/10.1016/j.mam.2010.02.006
Abstract
No abstract availableKeywords
This publication has 92 references indexed in Scilit:
- Distinct Genetic Alterations in the Mitogen-Activated Protein Kinase Pathway Dictate Sensitivity of Thyroid Cancer Cells to Mitogen-Activated Protein Kinase Kinase 1/2 InhibitionThyroid®, 2009
- Phase II Trial of Sorafenib in Metastatic Thyroid CancerJournal of Clinical Oncology, 2009
- Notch1 mediates growth suppression of papillary and follicular thyroid cancer cells by histone deacetylase inhibitorsMolecular Cancer Therapeutics, 2009
- Targeting RET for thyroid cancer therapyBiochemical Pharmacology, 2009
- Prospects for Epigenetic EpidemiologyAmerican Journal of Epidemiology, 2008
- Phase II Trial of Sorafenib in Advanced Thyroid CancerJournal of Clinical Oncology, 2008
- MicroRNA Expression Profiling of Thyroid Tumors: Biological Significance and Diagnostic UtilityJournal of Clinical Endocrinology & Metabolism, 2008
- Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancerNature Genetics, 2005
- Evolving anticancer drug valproic acid: Insights into the mechanism and clinical studiesMedicinal Research Reviews, 2005
- The history of cancer epigeneticsNature Reviews Cancer, 2004